Cargando…
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
BACKGROUND: Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in epithelial ovarian cancer (EOC). It doesn’t exist a consolidated criteria to predict optimal surgical resection at interval debulking surgery (IDS). The aim of this study is to develop a p...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975698/ https://www.ncbi.nlm.nih.gov/pubmed/29843747 http://dx.doi.org/10.1186/s13048-018-0415-y |
_version_ | 1783327037202628608 |
---|---|
author | Ghisoni, Eleonora Katsaros, Dionyssios Maggiorotto, Furio Aglietta, Massimo Vaira, Marco De Simone, Michele Mittica, Gloria Giannone, Gaia Robella, Manuela Genta, Sofia Lucchino, Fabiola Marocco, Francesco Borella, Fulvio Valabrega, Giorgio Ponzone, Riccardo |
author_facet | Ghisoni, Eleonora Katsaros, Dionyssios Maggiorotto, Furio Aglietta, Massimo Vaira, Marco De Simone, Michele Mittica, Gloria Giannone, Gaia Robella, Manuela Genta, Sofia Lucchino, Fabiola Marocco, Francesco Borella, Fulvio Valabrega, Giorgio Ponzone, Riccardo |
author_sort | Ghisoni, Eleonora |
collection | PubMed |
description | BACKGROUND: Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in epithelial ovarian cancer (EOC). It doesn’t exist a consolidated criteria to predict optimal surgical resection at interval debulking surgery (IDS). The aim of this study is to develop a predictive model of complete cytoreduction at IDS. METHODS: We, retrospectively, analyzed 93 out of 432 patients, with advanced EOC, underwent neoadjuvant chemotherapy (NACT) and IDS from January 2010 to December 2016 in two referral cancer centers. The correlation between clinical-pathological variables and residual disease at IDS has been investigated with univariate and multivariate analysis. A predictive score of cytoreduction (PSC) has been created by combining all significant variables. The performance of each single variable and PSC has been reported and the correlation of all significant variables with progression free survival (PFS) has been assessed. RESULTS: At IDS, 65 patients (69,8%) had complete cytoreduction with no residual disease (R = 0). Three criteria independently predicted R > 0: age ≥ 60 years (p = 0.014), CA-125 before NACT > 550 UI/dl (p = 0.044), and Peritoneal Cancer Index (PCI) > 16 (p < 0.001). A PSC ≥ 3 has been associated with a better accuracy (85,8%), limiting the number of incomplete surgeries to 16,5%. Moreover, a PCI > 16, a PSC ≥ 3 and the presence of R > 0 after IDS were all significantly associated with shorter PFS (p < 0.001, p < 0.001 and p = 0.004 respectively). CONCLUSIONS: Our PSC predicts, in a large number of patients, complete cytoreduction at IDS, limiting the rate of futile extensive surgeries in case of presence of residual tumor (R > 0). The PSC should be prospectively validated in a larger series of EOC patients undergoing NACT-IDS. |
format | Online Article Text |
id | pubmed-5975698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59756982018-05-31 A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience Ghisoni, Eleonora Katsaros, Dionyssios Maggiorotto, Furio Aglietta, Massimo Vaira, Marco De Simone, Michele Mittica, Gloria Giannone, Gaia Robella, Manuela Genta, Sofia Lucchino, Fabiola Marocco, Francesco Borella, Fulvio Valabrega, Giorgio Ponzone, Riccardo J Ovarian Res Research BACKGROUND: Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in epithelial ovarian cancer (EOC). It doesn’t exist a consolidated criteria to predict optimal surgical resection at interval debulking surgery (IDS). The aim of this study is to develop a predictive model of complete cytoreduction at IDS. METHODS: We, retrospectively, analyzed 93 out of 432 patients, with advanced EOC, underwent neoadjuvant chemotherapy (NACT) and IDS from January 2010 to December 2016 in two referral cancer centers. The correlation between clinical-pathological variables and residual disease at IDS has been investigated with univariate and multivariate analysis. A predictive score of cytoreduction (PSC) has been created by combining all significant variables. The performance of each single variable and PSC has been reported and the correlation of all significant variables with progression free survival (PFS) has been assessed. RESULTS: At IDS, 65 patients (69,8%) had complete cytoreduction with no residual disease (R = 0). Three criteria independently predicted R > 0: age ≥ 60 years (p = 0.014), CA-125 before NACT > 550 UI/dl (p = 0.044), and Peritoneal Cancer Index (PCI) > 16 (p < 0.001). A PSC ≥ 3 has been associated with a better accuracy (85,8%), limiting the number of incomplete surgeries to 16,5%. Moreover, a PCI > 16, a PSC ≥ 3 and the presence of R > 0 after IDS were all significantly associated with shorter PFS (p < 0.001, p < 0.001 and p = 0.004 respectively). CONCLUSIONS: Our PSC predicts, in a large number of patients, complete cytoreduction at IDS, limiting the rate of futile extensive surgeries in case of presence of residual tumor (R > 0). The PSC should be prospectively validated in a larger series of EOC patients undergoing NACT-IDS. BioMed Central 2018-05-30 /pmc/articles/PMC5975698/ /pubmed/29843747 http://dx.doi.org/10.1186/s13048-018-0415-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Ghisoni, Eleonora Katsaros, Dionyssios Maggiorotto, Furio Aglietta, Massimo Vaira, Marco De Simone, Michele Mittica, Gloria Giannone, Gaia Robella, Manuela Genta, Sofia Lucchino, Fabiola Marocco, Francesco Borella, Fulvio Valabrega, Giorgio Ponzone, Riccardo A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title_full | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title_fullStr | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title_full_unstemmed | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title_short | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
title_sort | predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975698/ https://www.ncbi.nlm.nih.gov/pubmed/29843747 http://dx.doi.org/10.1186/s13048-018-0415-y |
work_keys_str_mv | AT ghisonieleonora apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT katsarosdionyssios apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT maggiorottofurio apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT agliettamassimo apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT vairamarco apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT desimonemichele apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT mitticagloria apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT giannonegaia apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT robellamanuela apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT gentasofia apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT lucchinofabiola apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT maroccofrancesco apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT borellafulvio apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT valabregagiorgio apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT ponzonericcardo apredictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT ghisonieleonora predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT katsarosdionyssios predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT maggiorottofurio predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT agliettamassimo predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT vairamarco predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT desimonemichele predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT mitticagloria predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT giannonegaia predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT robellamanuela predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT gentasofia predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT lucchinofabiola predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT maroccofrancesco predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT borellafulvio predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT valabregagiorgio predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience AT ponzonericcardo predictivescoreforoptimalcytoreductionatintervaldebulkingsurgeryinepithelialovariancanceratwocentersexperience |